Literature DB >> 12126222

Safety and efficacy of controlled-release oxycodone: a systematic literature review.

D Gary Rischitelli1, Sean H Karbowicz.   

Abstract

Prescriptions for controlled-release oxycodone, a narcotic analgesic, recently contributed to a dramatic increase in pharmacy costs for a large private insurance company. To determine whether this agent offered clinical benefits over other available drugs that would justify its significantly greater cost, a systematic review of 16 clinical trials was undertaken. The review suggested that immediate-release and controlled-release preparations of oxycodone have similar efficacy and comparable side effect profiles. Controlled-release oxycodone has the advantage of less frequent dosing than immediate-release oxycodone; however, other agents may be dosed infrequently at much lower costs. For patients requiring a controlled-release opioid treatment, controlled-release morphine and methadone should be considered because they appear to be as effective as oxycodone and cost considerably less. Controlled-release oxycodone may be appropriate for some patients, particularly if they cannot tolerate other controlled-release or long-acting opioid analgesics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126222     DOI: 10.1592/phco.22.11.898.33628

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  10 in total

Review 1.  Strong opioids in pediatric palliative medicine.

Authors:  Richard D W Hain; Angela Miser; Mary Devins; W Hamish B Wallace
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 2.  Opioids in people with cancer-related pain.

Authors:  Columba Quigley
Journal:  BMJ Clin Evid       Date:  2008-07-31

Review 3.  The United States opioid epidemic.

Authors:  Jennifer Lyden; Ingrid A Binswanger
Journal:  Semin Perinatol       Date:  2019-01-14       Impact factor: 3.300

4.  [Oral controlled-release oxycodone for the treatment of chronic pain. Data from 4196 patients].

Authors:  J Gaertner; M Frank; B Bosse; R Sabatowski; F Elsner; T Giesecke; L Radbruch
Journal:  Schmerz       Date:  2006-02       Impact factor: 1.107

5.  Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.

Authors:  Wenfang B Fang; Michelle R Lofwall; Sharon L Walsh; David E Moody
Journal:  J Anal Toxicol       Date:  2013-06-05       Impact factor: 3.367

6.  Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease.

Authors:  Xu Yue; Torsten Falk; Leslie A Zuniga; Lajos Szabò; Frank Porreca; Robin Polt; Scott J Sherman
Journal:  Brain Res       Date:  2011-07-23       Impact factor: 3.252

7.  Comparison of Response of DRI Oxycodone Semiquantitative Immunoassay With True Oxycodone Values Determined by Liquid Chromatography Combined With Tandem Mass Spectrometry: Sensitivity of the DRI Assay at 100 ng/ml Cut-Off and Validity of Semiquantitative Value.

Authors:  R Brent Dixon; Bonnette Davis; Amitava Dasgupta
Journal:  J Clin Lab Anal       Date:  2015-02-25       Impact factor: 2.352

8.  The promotion and marketing of oxycontin: commercial triumph, public health tragedy.

Authors:  Art Van Zee
Journal:  Am J Public Health       Date:  2008-09-17       Impact factor: 9.308

Review 9.  Oxycodone: a pharmacological and clinical review.

Authors:  A Ordóñez Gallego; M González Barón; E Espinosa Arranz
Journal:  Clin Transl Oncol       Date:  2007-05       Impact factor: 3.405

10.  A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity.

Authors:  Paul R Chelminski; Timothy J Ives; Katherine M Felix; Steven D Prakken; Thomas M Miller; J Stephen Perhac; Robert M Malone; Mary E Bryant; Darren A DeWalt; Michael P Pignone
Journal:  BMC Health Serv Res       Date:  2005-01-13       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.